Issue link: https://beckershealthcare.uberflip.com/i/948573
32 DEVICES & IMPLANTS Stryker Sees $12.4B Net Sales in 2017; Neurotechnology, Spine Sales Reach $2.2B — 9 Highlights By Megan Wood S tryker reported its preliminary results for the fourth quarter and full year of 2017. Here are five highlights: 1. e company reported a 10 percent boost of net sales to $3.5 billion in the fourth quar- ter of 2017. 2. For the full year, net sales hit $12.4 billion, a 9.9 percent jump over 2016. 3. Domestically, net sales reached $2.5 billion in the fourth quarter and $9.1 billion for the full year of 2017. International sales reached $1 billion in the fourth quarter and $3.4 bil- lion for the full year of 2017. 4. In the fourth quarter of 2017, the following segments grew: • Neurotechnology and spine— 11.5 percent • Orthopedics — 8.1 percent • MedSurg —10.9 percent 5. For the full year of 2017, the following seg- ments increased: • Neurotechnology and spine — 8.2 percent • Orthopedics — 6.6 percent • MedSurg — 13.6 percent 6. Neurotechnology and spine net sales in- creased to $600 million in the fourth quarter and $2.2 billion for the full year of 2017. 7. e orthopedics net sales reached $1.3 bil- lion for the fourth quarter and $4.7 billion for the full year of 2017. Stryker installed 35 Mako robots around the world in the fourth quarter; U.S. knee sales increased 10.5 per- cent in the quarter. 8. MedSurg net sales rose to $1.6 billion for the fourth quarter and $5.6 billion for the full year of 2017. 9. Stryker anticipates 2017 adjusted net earn- ings per diluted share to land near the high end of the previously reported range of $6.45 to $6.50 billion. n J&J's 2017 Full-Year Orthopedics Sales Fall Flat, Spine Business Line Sales Drop: 5 Things to Know By Mackenzie Garrity J ohnson & Johnson released its fourth quarter and full-year financial results for 2017. Here are five things to know: 1. Within the orthopedics segment, J&J reported $2.34 billion in fourth quarter sales, a 2 percent drop compared to fourth quarter sales in 2016. 2. J&J's orthopedic segment also saw a dip in 2017 full-year sales from $9.33 billion in 2016 to $9.25 billion in 2017. This represents a 0.8 percent decline. 3. U.S. orthopedic sales dropped 2.3 percent in the fourth quar- ter, totaling $1.38 billion. International sales also decreased from $965 million in 2016 to $950 million in the fourth quarter of 2017. 4. Concerning the company's orthopedic medical devices, J&J's hip and trauma lines were the only two segments to experience year-over-year growth. The hip line grew 2.4 percent to $1.39 billion while the trauma line grew 1.8 percent to $2.61 billion. 5. In the fourth quarter, J&J reported major declines to its spine business line. For the year-end, the company reported a 4 per- cent drop in sales to $3.72 billion. n Life Spine Reports 493% 2017 Revenue Increase for ProLift Expandable Spacer System: 4 Highlights By Megan Wood L ife Spine saw a 493 percent boost in revenues from its ProLift Expandable Spacer System in 2017, compared to that of 2016. Here are four highlights: 1. The ProLift offers reduced graft subsidence. 2. The company's core solutions include ProLift, Ti- BOW and LONGBOW, all designed to enhance sur- gical efficiency and patient outcomes. 3. The ProLift and LONGBOW cut down multiple in- strument passes that risk neural structures. 4. Life Spine is also pushing additional Micro-Invasive Technologies with its AVATAR Percutaneous Screw System, AILERON Interspinous System, SIMPACT and TRI-FIN SI Joint Fixation and the CENTRIC retractor family. n